Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, announce that they are ...

Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies will be funded by the Bill & Melinda Gates Foundation to assess the added ...

Revenue: Record first-quarter revenue, clearly above EUR 1 million. Gross Margin: Achieved a new record gross margin of 94%. Operating Expenses: Reduced by 31% compared to the previous year. Income: ...

Nanoform continues to take logarithmic steps. In two years, we went from two PoC projects signed in 4Q19 to two GMP projects signed in 4Q21. During the same time the cumulative number of started PoCs ...

Nanoform and Herantis Pharma's proof of concept project evaluating the application of the nanoforming process has been successful. Nanoform, a nanoparticle medicine-enabling company, has revealed that ...

Revenue and Other Operating Income: Better performance this year compared to last year. Customer Payments: Growing faster than revenues recognized, indicating strong cash flow. Quarterly Cash Burn: ...

- In February, Nanoform and Herantis Pharma Plc signed a Biologics Proof of Concept Agreement aiming to enhance nasal drug delivery to the brain of Herantis’ CDNF therapies for Parkinson’s disease ...

After three years of large investments in personnel, systems and equipment, the focus has shifted from building capacity to improving productivity and the operating free cashflow. The fourth quarter ...

HELSINKI, Dec. 17, 2020 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug development company, today announced ...

Nanoform Finland will be initiating the first human trial of a drug candidate nanoformed using the company’s CESS technology in 2020. Nanoform Finland has revealed, in an Oct. 20, 2020 press release, ...

HELSINKI, Nov. 25, 2021 /PRNewswire/ -- The strong momentum continues: all near-term business targets for 2021 achieved, rapid customer project intake accelerating, commercial team in Europe expanded, ...